PharmacoEconomics & Outcomes News
Volume 823, Issue 1, March 2019
Lump sum agreements may allow universal access to drugs
Moon S, et al.
Australia’s agreement to spend about 1 billion Australian dollars (US $766 million) over 5 years in exchange for an unlimited volume of hepatitis C drugs suggests that, under certain conditions, innovative approaches to payment can remove price as a barrier to access.